Researchers from Case Western Reserve University, the University of Virginia, Cleveland Clinic, the University of Maryland School of Medicine, University Hospitals Cleveland Medical Center, the Louis Stokes Veterans Affairs Medical Center (Cleveland, OH), and CVPath Institute, Inc. (Gaithersburg, MD) have identified a new target to treat atherosclerosis, a condition where plaque clogs arteries and causes major cardiac issues, including stroke and heart attack. The researchers identified an inflammation-reducing molecule, called itaconate, and developed a new lipid nanoparticle-based treatment that allows itaconate to accumulate in plaque and bone marrow, where it reduces inflammation. "We've found that itaconate is crucial to the diet's ability to stabilize plaques and reduce inflammation, which has been a mystery until now," said Andrei Maiseyeu, one of the scientists involved in this study. "This discovery marks a major leap forward in the understanding of how diet-induced plaque resolution occurs at a molecular level."
An official website of the United States government.